| Today's Big NewsOct 10, 2022 |
| By Max Bayer Merck's sotatercept passed a critical phase 3 test for patients with pulmonary arterial hypertension, improving their distance in the six-minute walk test. The results have teed the company up to head to regulators and emphasize the lofty ambitions Merck has for the drug. |
|
|
|
By Angus Liu Hua Medicine has spent over a decade on one medicine—a diabetes candidate bought from Roche. Now under a partnership with Bayer, the drug has snagged a global first-in-class nod in China. |
By Conor Hale In light of the country’s expected growth as a medtech market, Siemens Healthineers has made the decision to split China out from the Asia-Pacific region at the corporate level, elevating it to its own seat at the company’s table. |
By Frank Diamond The elusiveness of generally agreed-upon diagnostic and treatment tools for long COVID begs the question: What should health plans pay for? |
By Nick Paul Taylor ImmunityBio’s push to hire 300 people at its New York facility in 30 months has made a bad start. Rather than add to its headcount, Patrick Soon-Shiong’s biotech has outlined plans to lay off 38 people by the end of the year. |
By Ben Adams AbbVie’s autoimmune JAK inhibitor Rinvoq topped the TV drug ad spending list for the third month in a row, keeping fierce rival Regeneron in second place, though only just. |
By Max Bayer BMS-backed Immatics is touting early phase 1 data of its cell therapy program and looking to fundraise off of it, seeking $110 million in a new public offering. It's the most robust data provided by the company to date, although the most promising figures are from just 12 patients. |
By Robert King HHS released a new report Friday detailing the benefits of COVID-19 vaccination and its impact on hospitalizations amid signs the administration's booster campaign is falling flat. |
By Andrea Park Vocal biomarkers have been linked to cardiovascular and respiratory conditions including COVID-19, as well as neurological diseases like depression, anxiety and even dementia—the last of which is in the crosshairs for speech analysis AI developer Winterlight Labs. |
By Conor Hale The company’s Glacios 2 cryo-transmission electron microscope is designed for biopharma researchers that may have varying experience levels with the technique. |
By Fraiser Kansteiner As Amneal winds down operations at its oral solids site in Hauppauge, New York, the company has disclosed 13 job cuts planned to go into effect “on or about December 31, 2022,” according to a Worker Adjustment and Retraining Notification (WARN) Act notice in the state. |
By Robert King Medicare Advantage enrollment starts this week as the program is more popular than ever. This report details some of the key trends and issues to watch out for, from star ratings to risk adjustment. |
By Andrea Park Fresh off the U.S. debut of Senseonics’ Eversense E3 continuous glucose monitor system, the system's distributor Ascensia Diabetes Care has now completed its initial launch in Europe, too. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk about trial results for Eisai and Biogen's Alzheimer’s drug, which were surprisingly good, and we dig into what comes next. We also discuss how Pfizer is ramping up its DTC ad campaign for its COVID shots, most recently spending big on a booster ad for the NFL season. |
|
|---|
|
|
|
Monday, October 17, 2022 | 11am ET / 8am PT Given the wide array of post transcriptional and post translational regulatory processes that govern cellular dynamics, additional omics types are needed to capture a more comprehensive understanding of the molecular landscape of a tumor.Register now to learn more. 
|
|
eBook Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT Data |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
